Home›Clinical trials›A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

A study testing whether a GLP-1 medicine from Novo Nordisk, semaglutide, can help with weight.

Who can join
Adults 18+, are overweight.
What you take
semaglutide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
How long it lasts
The full study runs about 2.1 years; your own time in it is usually shorter.
What you get
The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
Phase Phase 3Sponsor Novo Nordisk A/SDrug semaglutideClass GLP-1 RASites 46 USEnrollment target 650

What this study is for

Primary condition: Overweight. Also studied in: Obesity.

Full scientific study title: A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide.

Who can join

Age18 and upSexAny

Adults 18+, are overweight. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Male or female (sex at birth).
  • Age 18 years or above at the time of signing the informed consent.

Key exclusion criteria

  • Glycated haemoglobin (HbA1c) >= 6.5% (48 millimoles per mole [mmol/mol]) as measured by the central laboratory at screening.
  • History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records.
  • Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues within 1 year before screening.

Where this study is enrolling

This trial has 46 sites across 16 states. Contact a site coordinator directly to start screening.

California4 sites
  • First Valley Medical Group
    Lancaster, California
  • Desert Oasis Healthcare
    Palm Springs, California
  • Western University of Health Sciences
    Pomona, California
  • Artemis Insitute for Clin Res
    San Diego, California
District of Columbia1 site
  • Med Home Development Grp
    Washington D.C., District of Columbia
Florida10 sites
  • Encore Medical Research LLC
    Hollywood, Florida
  • NextPhase Research
    Hollywood, Florida
  • Jacksonville Ctr Clin Res
    Jacksonville, Florida
  • PharmaDev Clinical Research Institute LLC
    Miami, Florida
  • South Broward Research LLC
    Miramar, Florida
  • Essence MD Research
    Naples, Florida
  • Florida Inst For Clin Res LLC
    Orlando, Florida
  • Oviedo Medical Research, LLC
    Oviedo, Florida
  • Palm Beach Research Center
    West Palm Beach, Florida
  • Encore Medical Research of Weston
    Weston, Florida
Georgia2 sites
  • Conquest Research
    Atlanta, Georgia
  • Eastside Bariatric and Gen Surg
    Snellville, Georgia
Illinois2 sites
  • Chicago Research Center, Inc
    Chicago, Illinois
  • Endeavor Health
    Skokie, Illinois
Indiana1 site
  • Midwest Inst For Clin Res
    Indianapolis, Indiana
Louisiana1 site
  • Southern Clin Research
    Zachary, Louisiana
Missouri1 site
  • Amicis Centers of Clinical Research
    St Louis, Missouri
New York2 sites
  • Ichor Research
    Syracuse, New York
  • Southgate Medical Group, LLP
    West Seneca, New York
North Carolina3 sites
  • University of North Carolina
    Chapel Hill, North Carolina
  • PharmQuest Life Sciences LLC
    Greensboro, North Carolina
  • Piedmont Healthcare/Research
    Statesville, North Carolina
North Dakota1 site
  • Lillestol Research LLC
    Fargo, North Dakota
Pennsylvania1 site
  • Geisinger Clinic
    Danville, Pennsylvania
South Carolina3 sites
  • Medical University Of South Carolina
    Charleston, South Carolina
  • Hillcrest Clinical Research
    Simpsonville, South Carolina
  • Spartanburg Medical Research
    Spartanburg, South Carolina
Texas10 sites
  • Amarillo Med Spec LLP
    Amarillo, Texas
  • Texas Diabetes & Endocrinology
    Austin, Texas
  • Pinnacle Clinical Research
    Brownsville, Texas
  • Osvaldo A. Brusco MD
    Corpus Christi, Texas
  • UT Southwestern Med Center
    Dallas, Texas
  • Epic Medical Research
    DeSoto, Texas
  • Houston Research Institute
    Houston, Texas
  • The Endocrine Center
    Houston, Texas
  • Sleep Therapy Research Center
    San Antonio, Texas
  • Olympus Clinical Research
    Sugar Land, Texas
Virginia2 sites
  • National Clin Res Inc.
    Richmond, Virginia
  • Gastroent Consult of SW VA
    Roanoke, Virginia
Washington2 sites
  • Rainier Clin Res Ctr Inc
    Renton, Washington
  • Seattle Clinical Research Center
    Seattle, Washington

Timeline

Started enrolling: 2026-09-22. Expected completion: 2028-10-10. Last updated on ClinicalTrials.gov: 2026-06-25.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact
Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.